Global Assessment Regarding Legal Matters in Healthcare and Life Sciences, Based on IBA Committee's Survey Results
The International Bar Association (IBA) Healthcare and Life Sciences Law Committee's 2025 survey offers valuable insights into Ireland's healthcare financing and reimbursement landscape. The survey, featuring associates such as Aoibhín Ní Dhubháin, Brónach Rafferty, Colin Kavanagh (Partner), Orla Clayton (Of Counsel), Bridget Clinton (Senior Associate), and Robert Byrne, provides an in-depth analysis of the current legal and regulatory challenges and evolving market dynamics in Ireland's healthcare sector.
The survey delves into various aspects, including the impact of legislative changes, reimbursement frameworks, and legal compliance issues affecting healthcare providers, payers, and pharmaceutical companies in Ireland’s healthcare system. The survey also discusses Ireland's dual public and private healthcare systems and the roles of regulatory bodies like the Health Service Executive (HSE) and the Health Products Regulatory Authority (HPRA).
Moreover, the survey is part of a comprehensive legal guide that reviews major topics and trends concerning healthcare financing and reimbursement across more than 50 countries. One of the key legal frameworks mentioned in the survey is the Health Act 2013.
The survey also addresses the impact of COVID-19 on healthcare spending in Ireland, providing insights that are crucial for stakeholders planning strategic legal and financial approaches in Ireland's healthcare system. However, for a detailed and authoritative summary of the IBA Healthcare and Life Sciences Law Committee's 2025 survey findings specific to Ireland’s healthcare financing and reimbursement, consulting the IBA's official publications or reports released in July 2025 is recommended.
The survey further explores ongoing legislative developments in Ireland's healthcare financing and reimbursement, aligning with global movements towards sustainable healthcare spending and enhanced patient access. These insights are vital for stakeholders planning strategic legal and financial approaches in Ireland's healthcare system, focusing on regulatory shifts, challenges in reimbursement practices, pricing transparency, and innovation in healthcare financing.
The Life Sciences Group is featured in the Ireland section of the survey, demonstrating the group's expertise and extensive involvement in advising on healthcare financing matters in Ireland. These insights provide guidance on navigating complex healthcare reimbursement processes in Ireland’s evolving financial environment.
The survey delves into the intersection of science and health-and-wellness within Ireland's healthcare sector, providing insights on the role of regulatory bodies like the Health Products Regulatory Authority (HPRA) in overseeing pharmaceutical products. The survey also discusses the impact of science and innovation on healthcare financing, offering vital guidance for stakeholders navigating reimbursement processes in Ireland's evolving financial environment.
